A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
Public ClinicalTrials.gov record NCT00148486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
Study identification
- NCT ID
- NCT00148486
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 261 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2003 (Type not available)
- Primary completion
- Mar 2005 (Actual)
- Completion
- Not listed
- Last update posted
- Oct 29, 2013
Started 2003
United States locations
- U.S. sites
- 47
- U.S. states
- 20
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pivotal Reaserch Centers | Peoria | Arizona | — | — |
| Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| PMDI | Fountain Valley | California | — | — |
| Boehringer Ingelheim Investigational Site | Fresno | California | — | — |
| Boehringer Ingelheim Investigational Site | Irvine | California | — | — |
| Boehringer Ingelheim Investigational Site | Ocenside | California | — | — |
| Boehringer Ingelheim Investigational Site | Oxnard | California | — | — |
| West Los Angeles VA Medical Center | West Los Angeles | California | — | — |
| Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| UCONN Health Center | Farmington | Connecticut | — | — |
| 60 Temple St | New Haven | Connecticut | — | — |
| Boehringer Ingelheim Investigational Site | Boca Raton | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Bradenton | Florida | — | — |
| University of Florida | Gainsville | Florida | — | — |
| Sunrise Clinical Research | Hollywood | Florida | — | — |
| Department of Neurology | Miami | Florida | — | — |
| Miami Research Associates | Miami | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Ocala | Florida | — | — |
| Renstar Medical Research | Ocala | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| CNS Clinical Trials | Saint Piresburg | Florida | — | — |
| Movement Disorder Center | Tampa | Florida | — | — |
| University of Southern Florida | Tampa | Florida | — | — |
| Department of Neurological Sciences | Chicago | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Fort Wayne | Indiana | — | — |
| Outpatient Clinical Research Facility | Indianapolis | Indiana | — | — |
| Boehringer Ingelheim Investigational Site | Kansas City | Kansas | — | — |
| Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| Boehringer Ingelheim Investigational Site | Scarborough | Maine | — | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| Future Care Studies | Springfield | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Traverse City | Michigan | — | — |
| Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| University of Minesota | Minneapolis | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| University of Nebraska Medical Center | Omaha | Nebraska | — | — |
| Global Medical Institutes LLC | Toms River | New Jersey | — | — |
| Upstate Clinical Resaerch LLC | Albany | New York | — | — |
| Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| Boehringer Ingelheim Investigational Site | Wiston-Salem | North Carolina | — | — |
| Ohio State University Medical Center | Columbus | Ohio | — | — |
| Neurology Specialists Inc. | Dayton | Ohio | — | — |
| St. John's Doctor Building | Tulsa | Oklahoma | — | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | — | — |
| The Methodist Hospital | Houston | Texas | — | — |
| Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| North Texas Neurology Associates | Wichita Falls | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00148486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2013 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00148486 live on ClinicalTrials.gov.